Lung Infection Medication Recalled Nationwide Over Possible Bacterial Contamination

Drug maker Bionpharma Inc. has not yet received any reports of adverse events related to the recall.

A combination of photos show Atovaquone Oral Suspension, 750 mg/mL, for which a voluntary nationwide recall was issued by the company over potential bacterial contamination. Bionpharma Inc. via FDA

Drug manufacturer Bionpharma Inc. is voluntarily recalling one of its medications used to treat serious lung infections, over possible Cohnella bacteria contamination, according to the U.S. Food and Drug Administration (FDA).

The Princeton, New Jersey-headquartered company is recalling single batches of its 750 mg/mL Atovaquone Oral Suspension, a Sept. 18 FDA notice said.